Valmark Advisers, Inc. Tarsus Pharmaceuticals, Inc. Transaction History
Valmark Advisers, Inc.
- $7.6 Billion
- Q3 2025
A detailed history of Valmark Advisers, Inc. transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Valmark Advisers, Inc. holds 5,500 shares of TARS stock, worth $387,805. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,500
Previous 5,500
-0.0%
Holding current value
$387,805
Previous $222,000
46.85%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TARS
# of Institutions
215Shares Held
46.9MCall Options Held
7.8KPut Options Held
0-
Black Rock Inc. New York, NY3.27MShares$230 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.11MShares$219 Million1.94% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.98MShares$210 Million5.63% of portfolio
-
Jennison Associates LLC2.6MShares$184 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$173 Million5.96% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.88B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...